Unique structural features of firmonertinib enhance binding and activity against EGFR mutant proteins including ex20ins mutant proteins in cell ...

Credit: AstraZeneca. Tagrisso, a kinase inhibitor, is available as 40mg and 80mg strength tablets in 30-count bottles. The Food and Drug Administration (FDA) has approved Tagrisso ® (osimertinib) in ...

"The real-time PCR using plasma or body fluids could be a suitable first test for the detection of EGFR mutations." –Lee et al., Asia-Pacific Journal of Clinical Oncology, 2022 To this end, Kyunghoon ...

The study offers guidance to clinicians treating the roughly 10% of patients with rare EGFR mutations. Patients with non–small cell lung cancer (NSCLC) who have uncommon EGFR mutations appear to have ...

Effect of IKKϵ knock-down on prostate cancer xenograft growth. Background: Activating EGFR mutations have become a backbone in the therapy alogrithm for NSCLC as mutations predict significantly better ...

A retrospective analysis of real-world data showed that <1% of patients with NSCLC had co-mutations in HER2 and EGFR. Median time on treatment with TKIs was longer in patients with concurrent EGFR and ...

Michelle Afkhami, MD, of City of Hope, joins The American Journal of Managed Care® (AJMC®) for a discussion on EGFR exon 20 insertion positive mutations in non-small cell lung cancer. Michelle Afkhami ...

Approval is based on results from the Phase 3 PAPILLON study, which demonstrated RYBREVANT® plus chemotherapy reduced the risk of disease progression or death by 61 percent versus chemotherapy alone ...

Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...

According to real-world data, EGFR C797X mutation is deemed the leading resistance mechanism to treatment with Tagrisso in patients with non-small cell lung cancer. Certain features may make patients ...